Genmab A/S (GMAB) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Genmab A/S
Address
Carl Jacobsens Vej 30
Copenhagen, CD 2500
Denmark
Phone
45 70 20 27 28
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2638
First IPO Date
June 01, 2009
Key Executives
| Name | Title | Pay | Year Born |
| Jan van de Winkel | Co-Founder, President & Chief Executive Officer | 3.3M | 1961 |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 300,000 | 1975 |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director | 300,000 | 1973 |
| Christopher Cozic | Executive Vice President & Chief People Officer | 800,000 | 1979 |
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer | 900,000 | 1971 |
| Anthony Pagano | Executive Vice President & Chief Financial Officer | 1.1M | 1978 |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer | 1.3M | 1958 |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | 1.3M | 1973 |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 1.7M | 1971 |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer | 1.8M | 1968 |
Description
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
